利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.019 秒)

    PERFLUOROCARBON ASSOCIATED GAS EXCHANGE
    12.
    发明公开
    PERFLUOROCARBON ASSOCIATED GAS EXCHANGE 失效
    全氟烃相关气体交换

    公开(公告)号：EP0582570A4

    公开(公告)日：1994-07-13

    申请号：EP91920110

    申请日：1991-09-27

    申请人： UNIV PITTSBURGH

    发明人： FUHRMAN BRADLEY P

    IPC分类号： A61K31/02 ,  A61K31/025 ,  A61M16/00 ,  A61M16/14 ,  A61P11/00 ,  C07D307/18 ,  C07D309/08

    CPC分类号： A61M16/0054 ,  A61M16/0833 ,  A61M16/0841 ,  A61M2016/0027 ,  A61M2202/0476 ,  Y10S128/913

    摘要： Method and means for maintaining respiratory gas exchange by introducing into the pulmonary air passages (18) of a mammalian host a volume of perfluorocarbon liquid substantially equivalent to the pulmonary functional residual capacity of the host, maintaining respiratory gas exchange in the perfluorocarbon liquid-laden pulmonary air passages (18) by continuous positive pressure breathing or otherwise with a conventional gas respirator (12), for up to an hour or more, and thereafter evaporating the perfluorocarbon liquid from the pulmonary air passages. Useful for treating pulmonary surfactant deficiency or dysfunction.

    摘要翻译： 用于维持呼吸气体交换的方法和装置，通过向哺乳动物宿主的肺空气通道中引入一定体积的全氟化碳液体，其基本上等于宿主的肺功能残留能力，维持全氟化碳液体充满的肺空气通道中的呼吸气体交换 通过用常规呼吸器连续正压呼吸达一个小时以上，然后从肺部空气通道中蒸发全氟化碳液体。 用于治疗肺表面活性物质缺乏或功能障碍。

    Process to produce 2', 3'-Dideoxynucleosides
    15.
    发明公开
    Process to produce 2', 3'-Dideoxynucleosides 失效
    Verfahren zur Herstellung von 2'，3'-双脱氧核苷。

    公开(公告)号：EP0285884A2

    公开(公告)日：1988-10-12

    申请号：EP88104384.8

    申请日：1988-03-18

    申请人： Bristol-Myers Squibb Company

    发明人： Farina, Vittorio ,  Martin, John C. ,  Benigni, Daniel A-

    IPC分类号： C07D473/00 ,  C07D405/04 ,  C07D307/18

    CPC分类号： C07D473/00 ,  C07D405/04

    摘要： There is disclosed a novel process to produce 2ʹ,3ʹ-­dideoxynucleosides such as, for example, 2ʹ,3ʹ-dideoxy­cytidine, in high yields. More particularly, the various stereoisomers of 2ʹ,3ʹ-dideoxynucleosides are obtained. The α- and β-(L)-2ʹ,3ʹ-dideoxynucleosides and certain α-(D)-2ʹ,3ʹ-dideoxynucleosides are obtained as stereo­chemically pure compounds not heretofore obtained. The compounds so produced are useful as antiviral and antibiotic agents.

    摘要翻译： 公开了以高产率制备2'，3'-二脱氧核苷，例如2'，3'-双脱氧胞苷的新方法。 更具体地，获得2'，3'-二脱氧核苷的各种立体异构体。 获得α和β - （L）-2'，3'-二脱氧核苷和某些α - （D）-2'，3'-二脱氧核苷作为以前未获得的立体化学纯的化合物。 如此制备的化合物可用作抗病毒和抗生素。

    New 2,5-diaryl tetrahydrofurans and analogs thereof as paf-antagonists
    17.
    发明公开
    New 2,5-diaryl tetrahydrofurans and analogs thereof as paf-antagonists 失效
    新的2,5-DIARYL四氢呋喃和其类似物作为PAF拮抗剂

    公开(公告)号：EP0144804A3

    公开(公告)日：1986-01-08

    申请号：EP84113600

    申请日：1984-11-12

    申请人： MERCK & CO. INC.

    发明人： Biftu, Tesfaye ,  Hwang, San-Bao ,  Doebber, Thomas W. ,  Beattie, Thomas R. ,  Shen, Tsung-Ying

    IPC分类号： C07D307/12 ,  C07D307/18 ,  C07D307/20 ,  A61K31/34

    CPC分类号： C07D307/18 ,  C07C45/00 ,  C07C45/72 ,  C07D307/12 ,  C07D307/14 ,  C07D307/20 ,  C07C49/84

    摘要： Compounds of formula:
    are disclosed wherein R and R' independently are
    (a) hydrogen; (b) haloloweralkyl; (c) halo; (d) CONR 2 R 3 wherein R 2 and R 3 independently represent C 1-6 alkyl and hydrogen; (e) loweralkenyl; (f) -COR 2 (g) -CH 2 OR 2 ; (h) loweralkynyl; (i) -CH 2 -NR 2 R 3 ; (j) -CH 2 SR 2 ; (k) =0; or (I) -OR 2 ; Ar and Ar' are the same or different from each other and are (a) phenyl or substituted phenyl of formula
    where R 4 -R 8 independently represent H, RO-, R 2 S-, R 2 SO 2 -,CF 3 O-, CF 3 S-, R 2 R 3 N-, -OCH 2 CO 2 R 2 , -SO 2 NR 2 R 3 , -C0 2 R 2 , -NR 2 SO 2 R 3 , COR 2 , N0 2 , or CN or R 4 -R 5 , R 5 -R 6 , R 6 -R 7 and R 7 -R 8 are joined together forming a bridge;
    (b) pyrryl or substituted pyrryl; (c) furyl or substituted furyl; (d) pyridyl or substituted pyridyl; or (e) thiophene or substituted thiophene. These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and thereby are useful in the treatment of varous diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, adult respiratory distress syndrome, pain, and aggregation of platelets.